Zacks Small-Cap Research
Sponsored – Impartial - Comprehensive

April 23, 2019
David Bautz, PhD
312-265-9471
dbautz@zacks.com

scr.zacks.com
10 S. Riverside Plaza, Chicago, IL 60606

Soligenix, Inc. (SNGX-NASDAQ)

SNGX: Enrollment Target Reached for Interim Analysis of SGX942 Phase 3 Trial…

Based on our probability adjusted DCF model that takes into account potential future revenues from SGX301 and SGX942, SNGX is valued at $8.50 per share. This model is highly dependent upon continued clinical success of SGX301 and SGX942 and will be adjusted accordingly based upon future clinical results.

Current Price (04/23/19)	$0.71
Valuation	**$8.50**

OUTLOOK

On April 18, 2019, Soligenix, Inc. (SNGX) announced that patient enrollment in the Phase 3 clinical trial of SGX942 (dusquetide) is sufficient to allow for the planned interim efficacy analysis by the independent Data Monitoring Committee (DMC). The DMC can recommend either stopping the study for overwhelming efficacy, stopping the study for any serious safety concern, stopping the study for futility, continuing enrollment up to the pre-specified sample size of approximately 190, or re-estimating the sample size up or down to maintain the trial's statistical power. We anticipate the results of the interim analysis in September 2019. Currently, we estimate final enrollment of the trial should complete by the fourth quarter of 2019 with topline results likely in the first half of 2020, pending the outcome of the interim analysis.

SUMMARY DATA

52-Week High	**$2.10**
52-Week Low	**$0.71**
One-Year Return (%)	**-59.43**
Beta	**1.33**
Average Daily Volume (sh)	**196,952**
Shares Outstanding (mil)	**17**
Market Capitalization ($mil)	**$12**
Short Interest Ratio (days)	**N/A**
Institutional Ownership (%)	**10**
Insider Ownership (%)	**15**
Annual Cash Dividend	**$0.00**
Dividend Yield (%)	**0.00**
5-Yr. Historical Growth Rates	
Sales (%)	**15.3**
Earnings Per Share (%)	**N/A**
Dividend (%)	**N/A**
P/E using TTM EPS	**N/A**
P/E using 2018 Estimate	**-1.5**
P/E using 2019 Estimate	**-1.6**

Risk Level	**Above Avg.**
Type of Stock	**Small-Blend**
Industry	**Med-Biomed/Gene**

ZACKS ESTIMATES

Revenue
(in millions of $)

	Q1 (Mar)	Q2 (Jun)	Q3 (Sep)	Q4 (Dec)	Year (Dec)
2018	1.1 A	1.7 A	1.4 A	1.0 A	5.2 A
2019	1.3 E	1.4 E	1.4 E	1.5 E	5.6 E
2020					5.8 E
2021					6.0 E

Earnings per Share

	Q1 (Mar)	Q2 (Jun)	Q3 (Sep)	Q4 (Dec)	Year (Dec)
2017	-$0.27 A	-$0.18 A	-$0.11 A	-$0.17 A	-$0.67 A
2018	-$0.13 E	-$0.13 E	-$0.14 E	-$0.14 E	-$0.53 E
2019					-$0.48 E
2020					-$0.48 E

WHAT'S NEW

Business Update

Enrollment Target Reached for Interim Analysis of SGX942 Phase 3 Trial

On April 18, 2019, Soligenix, Inc. (SNGX) announced that it has reached the enrollment target for the Phase 3 clinical trial of SGX942 (dusquetide) to support the planned interim efficacy analysis by the independent Data Monitoring Committee (DMC). The Phase 3 DOM-INNATE (Dusquetide treatment in Oral Mucositis – by modulating INNATE immunity) clinical trial is evaluating SGX942 for the treatment of sever oral mucositis (OM) in patients with squamous cell carcinoma of the oral cavity and oropharynx undergoing chemoradiation therapy. The trial is being supported in part by a $1.5 million SBIR grant awarded by the National Institute of Dental and Craniofacial Research (NIDCR), a part of the NIH.

The possible DMC recommendations stemming from the interim analysis include: a) stopping the study for overwhelming efficacy; b) stopping the study for serious safety concern; c) stopping the study for futility; d) continuing enrollment in the study at the pre-specified sample size of approximately 190 subjects; or e) re-estimating sample size up or down to maintain the study's statistical power. We anticipate results from the interim analysis in September 2019.

In the meantime, the company will continue enrolling patients into the trial, and pending the outcome of the interim analysis, we currently estimate patient enrollment will complete in the fourth quarter of 2019 and topline results being announced in the first half of 2020.

Pediatric Investigation Plan for SGX942 Accepted by EMA

On April 9, 2019, Soligenix announced that the European Medicines Agency (EMA) has agreed to the company's Pediatric Investigation Plan (PIP) for SGX942. In addition, the EMA agreed that the company may defer conducting the PIP until successful completion of the ongoing Phase 3 DOM-INNATE clinical trial. All pharmaceuticals approved in Europe must have an approved PIP. In Soligenix's case, the company will be allowed to file a Marketing Authorization Application (MAA) for the adult indication prior to completion of the PIP due to the Pediatric Committee of the EMA permitting its deferral until the risk/benefit of SGX942 has been established in an adult population.

Non-Dilutive Funding from NJ Tax Program

On April 15, 2019, Soligenix announced the receipt of approximately $611,000 via the state of New Jersey's Technology Business Tax Certificate Transfer Program. The program allows for various technology companies to sell their Net Operating Loss (NOL) Carryovers and unused R&D Tax Credits to unaffiliated, corporate taxpayers in New Jersey. This is the ninth year that the company has received NOL funding and all told has received approximately $5 million over that span.

Expansion of IP Protection for IDR's

On April 4, 2019, Soligenix announced the US Patent and Trademark Office will issue U.S. Patent No. 10,253,068 titled "Novel Peptides for Treating and Preventing Immune-Related Disorders, Including Treating and Preventing Infection by Modulating Innate Immunity". The patent provides composition of matter protection for a number of innate defense regulator (IDR) analogs and includes therapeutic use claims in oral mucositis, colitis, and infectious disease, with and without the use of antibiotics.

Conclusion

We value Soligenix using a probability adjusted discounted cash flow analysis based on potential future revenues of SGX301 in CTCL and SGX942 in OM. For SGX301, we model for approval in 2021 and

peak revenues of approximately $200 million worldwide. Using a 70% probability of approval and a 13% discount rate leads to a net present value of $73 million. For SGX942, we model for approval in 2021 and peak revenues of approximately $350 million worldwide. Using a 60% probability of approval and a 13% discount rate leads to a net present value of $104 million. Combining the net present value for those two products with the company's current cash position, the potential cash from exercising warrants, and using a fully diluted share count of 25.0 million shares leads to a valuation of approximately $8.50 per share. Soligenix is currently trading at a significant discount to our valuation, and with two Phase 3 readouts due by the first half of 2020 we believe investors would be well served to take a closer look at the company in the leadup to those readouts.

PROJECTED FINANCIALS

Soligenix, Inc.	2018 A	Q1 E	Q2 E	Q3 E	Q4 E	2019 E	2020 E	2021 E
License Revenue	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0
Grant/Contract Revenue	$5.2	$1.3	$1.4	$1.4	$1.5	$5.6	$5.8	$6.0
SGX301	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0
SGX942	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0
Total Revenues	**$5.2**	**$1.3**	**$1.4**	**$1.4**	**$1.5**	**$5.6**	**$5.8**	**$6.0**
Cost of Revenue	$4.6	$1.0	$1.2	$1.2	$1.3	$4.7	$4.9	$5.1
Gross Income	**$0.6**	**$0.3**	**$0.2**	**$0.2**	**$0.2**	**$0.9**	**$0.9**	**$1.0**
Gross Margin	*12.3%*	*24.7%*	*14.3%*	*13.1%*	*13.3%*	*16.2%*	*15.5%*	*15.8%*
Research & Development	$6.8	$1.8	$1.8	$1.9	$1.9	$7.4	$8.2	$9.8
General & Administrative	$3.0	$0.8	$0.8	$0.8	$0.8	$3.2	$3.7	$4.0
Other Expenses	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0
Operating Income	($9.1)	($2.3)	($2.4)	($2.5)	($2.5)	($9.7)	($11.0)	($12.9)
Operating Margin	-	-	-	-	-	-	-	-
Other Income (Net)	$0.2	$0.1	$0.1	$0.1	$0.1	$0.2	$0.0	$0.0
Pre-Tax Income	**($8.9)**	**($2.2)**	**($2.4)**	**($2.5)**	**($2.5)**	**($9.5)**	**($11.0)**	**($12.9)**
Net Taxes (benefit)	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0
Tax Rate	*0.4%*	*0.0%*	*0.0%*	*0.0%*	*0.0%*	*0.0%*	*0.0%*	*0.0%*
Reported Net Income	**($8.9)**	**($2.2)**	**($2.4)**	**($2.5)**	**($2.5)**	**($9.5)**	**($11.0)**	**($12.9)**
Net Margin	-	-	-	-	-	-	-	-
Reported EPS	**($0.67)**	**($0.13)**	**($0.13)**	**($0.14)**	**($0.14)**	**($0.53)**	**($0.48)**	**($0.48)**
YOY Growth	-	-	-	-	-	-	-	-
Basic Shares Outstanding	13.2	17.7	17.9	18.0	18.1	17.9	23.0	27.0

Source: Zacks Investment Research, Inc. *David Bautz, PhD*

HISTORICAL STOCK PRICE

DISCLOSURES

The following disclosures relate to relationships between Zacks Small-Cap Research ("Zacks SCR"), a division of Zacks Investment Research ("ZIR"), and the issuers covered by the Zacks SCR Analysts in the Small-Cap Universe.

ANALYST DISCLOSURES

I, David Bautz, PhD, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report. I believe the information used for the creation of this report has been obtained from sources I considered to be reliable, but I can neither guarantee nor represent the completeness or accuracy of the information herewith. Such information and the opinions expressed are subject to change without notice.

INVESTMENT BANKING AND FEES FOR SERVICES

Zacks SCR does not provide investment banking services nor has it received compensation for investment banking services from the issuers of the securities covered in this report or article.
Zacks SCR has received compensation from the issuer directly or from an investor relations consulting firm engaged by the issuer for providing non-investment banking services to this issuer and expects to receive additional compensation for such non-investment banking services provided to this issuer. The non-investment banking services provided to the issuer includes the preparation of this report, investor relations services, investment software, financial database analysis, organization of non-deal road shows, and attendance fees for conferences sponsored or co-sponsored by Zacks SCR. The fees for these services vary on a per-client basis and are subject to the number and types of services contracted. Fees typically range between ten thousand and fifty thousand dollars per annum. Details of fees paid by this issuer are available upon request.

POLICY DISCLOSURES

This report provides an objective valuation of the issuer today and expected valuations of the issuer at various future dates based on applying standard investment valuation methodologies to the revenue and EPS forecasts made by the SCR Analyst of the issuer's business.
SCR Analysts are restricted from holding or trading securities in the issuers that they cover. ZIR and Zacks SCR do not make a market in any security followed by SCR nor do they act as dealers in these securities. Each Zacks SCR Analyst has full discretion over the valuation of the issuer included in this report based on his or her own due diligence. SCR Analysts are paid based on the number of companies they cover. SCR Analyst compensation is not, was not, nor will be, directly or indirectly, related to the specific valuations or views expressed in any report or article.

ADDITIONAL INFORMATION

Additional information is available upon request. Zacks SCR reports and articles are based on data obtained from sources that it believes to be reliable, but are not guaranteed to be accurate nor do they purport to be complete. Because of individual financial or investment objectives and/or financial circumstances, this report or article should not be construed as advice designed to meet the particular investment needs of any investor. Investing involves risk. Any opinions expressed by Zacks SCR Analysts are subject to change without notice. Reports or articles or tweets are not to be construed as an offer or solicitation of an offer to buy or sell the securities herein mentioned.